Racial differences in response to therapy for heart failure: Analysis of the Vasodilator-Heart Failure Trials

Journal of Cardiac Failure

Volumn 5, Issue 3, 1999, Pages 178-187

  Carson, Peter ^a   Ziesche, Susan ^b   Johnson, Gary ^c   Cohn, Jay N ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Vet Aff Coop Studs Prog C   (United States)

Author keywords

ACE inhibitors; Blacks; Heart failure; Hydralazine isosorbide dinitrate

Indexed keywords

VASODILATOR AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT OUTCOME;

EID: 0032836517     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90001-5     Document Type: Article

References (31)

1. Ghali JK, Cooper R, Ford E: Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73
2. Alexander M, Grumbach K, Selby J, Brown AF, Washington E: Hospitalization for congestive heart failure - explaining racial differences. JAMA 1995;274:1037-42
3. Whittle J, Conigliaro J, Good CB, Lofgren RP: Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs Medical System. N Engl J Med 1993;329:621-7
4. Gillum RF: Heart failure in the United States, 1970-1985. Am Heart J 1987;113:1043-5
5. Gillum RF: Pathophysiology of hypertension in blacks and whites. Hypertension 1979;1:468-75
6. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986;314:1547-52
7. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10
8. Veterans Administration Co-Operative Study Group on Antihypertensive Agents: Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982;14:97-101 (suppl S)
9. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers JR, Zemel MB, Curry C, Schoenberger J, Wright JT, Kirkendall W, Conradi EC, Jenkins P, McLean B, Massie B, Berenson G, Flamenbaum W: A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150: 1707-13
10. Passon PG, Beuler JD: A simplified radiometric assay for norepinephrine and epinephrine. Anal Biochem 1973;51: 618-31
11. Sealey JE: Plasma renin activity and plasma prorenin assays. Clin Chem 1991;37:1811-9
12. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16
13. Peniston RL, Lu DY, Papademetriou V, Fletcher RD: Severity of coronary artery disease in black and white veterans and likelihood of revascularization. J Am Coll Cardiol 1994;23:299A (abstr)
14. Joint National Committee: The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1985;144: 1045-57
15. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S: Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22:14-9 (suppl A)
16. Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Veterans Administration Cooperative Study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987;75:49-54 (suppl VI)
17. Johnson G, Carson P, Francis GS, Cohn JN, for the V-HeFT VA Cooperative Studies Group: Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy on Heart Failure (V-HeFT II). Circulation 1993;87:32-9 (suppl VI)
18. Ghali JK, Kadakia S, Cooper R, Ferlinz J: Precipitating factors leading to decompensation of heart failure: traits among urban blacks. Arch Intern Med 1988;148:2013-16
19. Cody RJ, Couit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J: Sodium and water balance in chronic congestive heart failure. J Clin Invest 1986;77:1441-52
20. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC: Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. Circulation 1989;80:299-305
21. Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C: The intravenous furosemide test: A simple way to evaluate renin responsiveness. Ann Intern Med 1976;84:639-45
22. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V-HeFT VA Cooperative Studies Group: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87:5-16 (suppl VI)
23. Mills PJ, Dimsdale JG, Ziegler MG, Neleson RA: Racial differences in epinephrine and beta adrenergic receptors. Hypertension 1995;25:88-91
24. Pratt JH, Menatunga AK, Bowsher RR, Henry BP: The interaction of norepinephrine excretion with blood pressure and race in children. J Hypertens 1992;10:93-6
25. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension-I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982;248:1996-2003
26. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension-II. Results of long-term therapy. JAMA 1982;248: 2004-11
27. Cody RJ, Laragh JH, Case DB, Atlas SA: Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 1983;5:36-42 (suppl III)
28. Pierpont GL, Cohn JN, Franciosa JA: Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest 1978; 73:8-13
29. Bauer JA, Fung H-L: Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84: 35-9
30. Münzel T, Kurz S, Rajagopalan S, Martin T, Berrington WR, Thompson JA, Fruman BA, Harrison DG: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest 1996;98:1465-70
31. Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, Elkayam U: Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-80